Health Condition 1: N17- Acute kidney failure Health Condition 2: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 3: N186- End stage renal disease
Conditions
Interventions
Intervention1: remdesivir: We will be checking pharmacokinetics of remdesivir. there is no comparator agent.
The dose is 200 mg on Day 1, followed by 100 mg for next 4 days.
The mode of administration
Sponsors
Department of nephrology
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with severe COVID19 and kidney disease [any one of the following â?? end stage kidney disease OR acute kidney injury OR kidney transplant recipients with acute graft dysfuntion. 2. Patients in whom the treating physician decides to start Remdesivir as a part of standard care. 3. Willing to give written, informed consent. 4. Participants of either gender 5. Age >18 years
Exclusion criteria
Exclusion criteria: 1. Patients with presumed or suspected diagnosis of COVID19 2. Patients with pregnancy 3. Patients with underlying liver disease [AST/ALT elevations > 5 times the upper limit of normal] 4. Patients with any known allergy of reaction to Remdesivir. 5. Patients requiring daily or more frequent dialysis sessions. 6. Patients in the AKI or transplant catergory who require dialysis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To evaluate the pharmacokinetics of SBECD in adult patients with severe covid19 and kidney disease.Timepoint: 1 YEAR | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the pharmacokinetics of Remdesivir in adult patients with severe covid19 and kidney disease To correlate the levels of SBECD and Remdesivir with any adverse events seen after administration of Remdesivir.Timepoint: 1 YEAR | — |
Countries
India
Contacts
Public ContactDr Divya Bajpai
Department of Nephrology
Outcome results
None listed